We assessed the long-term outcome of consecutive patients in the chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (INF-α) in Central and Northern Moravia between 1989 and 2006. Methods. A retrospective study focused on the response, prognostic factors and side-effects of INF-α. Results. 118 patients (67 males and 51 females, median age 50 years; range 18-71) were analyzed. The median followup was 82.6 months (12.4-212.6). Thirty-six patients (30.5%) achieved major cytogenetic response (CyR) in median of 18.3 months (3.7-47.3) and maintained it for a median of 64.0 months (7.0-176.0). Sixty-one patients treated with INF-α for more than 12 months had an overall survival (OS) of 137.0 months (95% CI 117.6-156.4). Eighteen (29.5%) achieved complete CyR (CCyR). 109 patients discontinued the treatment with INF-α because of hematologic or cytogenetic resistance in 53 (48.7%), progression of CML in 31 (28.4%) and intolerance to INF-α in 17 (15.6%) patients. The percentage of peripheral blasts, leukocyte count (>50x10 9 /L), splenomegaly, anemia (Hgb≤110 g/L) and Sokal score had statistical impact on the OS in univariate assessment but only the Sokal score remained significant in multivariate analysis. Additional cytogenetic abnormalities at diagnosis were associated with poor prognosis. Conclusions. In most patients, treatment with INF-α had to be stopped because of a failure to induce response, progression of CML or side-effects but nearly one third of patients treated at least for one year had a long-term benefit from INF-α. The best prognosis was associated with achievement of CCyR and negativity of BCR-ABL in nested RT-PCR.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm characterized by acquisition of the Philadelphia (Ph) chromosome in stem cells and their progeny 1 . The aberrant chromosome results of a reciprocal translocation between the long arms of chromosomes 9 and 22 t(9;22)(q34;q11), giving rise to the fusion gene BCR-ABL1. This fusion gene encodes for a constitutively active tyrosine kinase which has become the major therapeutic target of CML treatment today 2, 3 . Imatinib, a tyrosine kinase inhibitor (TKI) often exerts very rapid therapeutic response 4 that may be explained by targeting mature CML progenitors. However, responses achieved after imatinib therapy may not be durable 5 which could be a clinical correlation of CML stem cell resistance to TKIs. CML origin is supposed to arise from the transformed line of CD34+CD38-normal stem cells since these cells themselves and their progeny carry the BCR-ABL1 fusion gene 6 . CML stem cells share many biological properties with their normal counterparts 7 . Hematopoietic stem cells are largely quiescent and express high levels of the multidrug resistance-1 gene 8 that might limit imatinib uptake 9 .
In contrast to mature CML progenitors where BCR-ABL kinase is required for survival and self-renewal, in the case of CML stem cells, BCR-ABL seems to play only a subtle role and is not indispensable for their self-renewal 7, [10] [11] [12] . Interferon-alpha (INF-α) was one of the main treatment options before the discovery of TKIs. Reports of complete cytogenetic response (CCyR) and complete molecular response (CMR) achieved after INF-α therapy have been published 13 . Achieving CCyR and CMR was proved to be associated with excellent long-term prognosis 14 . Some patients maintained their CCyR even after discontinuation of INF-α and remained without any specific treatment 13 . In comparison with imatinib, CCyR after INF-α was achieved in a median of 19 months (6 months with imatinib) and was long-lasting 15 . There is laboratory 16 and clinical evidence showing that INF-α is effective in targeting quiescent CML stem cells insensitive to TKIs. Angstreich et al. tested in vitro sensitivity of primitive and differentiated CML progenitors to imatinib and INF-α proving that imatinib is more toxic to CML CFU-GM progenitors whereas INF-α had significantly greater activity against primitive Ph-positive progenitors 17 . INF-α exerts its wide range of effect via multiple pathways involved in cytokine gene expression, cell cycle regulation, differentiation, proliferation and apoptosis 18 . It also stimulates autologous cytotoxic T lymphocytes to specifically recognize BCR-ABL or BCR-ABL-dependent antigens like proteinase-3 (ref. 19 ). It was shown that INF-α, but not imatinib, triggers PR1-specific cytotoxic T lymphocyte responses 20 , a fact that is considered to be associated with responsiveness to INF-α in CML (ref. [20] [21] [22] ). In our long-term retrospective study, we evaluated the outcome of all consecutive CML patients treated in the Northern and Central Moravia regions with INF-α alone or in combination with cytosine arabinoside (Ara-C) or hydroxyurea, with special attention to treatment response, side-effects and assessment of prognostic factors.
MATERIALS AND METHODS
Patients and treatment
All consecutive patients with chronic phase CML diagnosed and treated with INF-α at the Department of Hemato-Oncology of the Faculty of Medicine and Dentistry, Palacky University in Olomouc in cooperation with regional hematologists between 1989 and 2006 were included in the analysis. Patients participating in clinical studies performed during the study period gave informed consent approved by the local Ethics Committee. Transplanted patients and patients whose data were collected in the EBMT and CAMELIA databases consented to data collection.
Diagnosis of CML was based on cytogenetic assessment with confirmation of the Ph chromosome and/or demonstration of the BCR-ABL1 fusion gene using nested RT-PCR or fluorescence in situ hybridization (FISH). Cytogenetic examinations were performed according to the standard procedure from bone marrow cells at the time of starting INF-α therapy and then once every six months or in cases of suspected progression. At least 20 mitoses were analyzed. Interphase FISH with LSI BCR-ABL ES and/or LSI BCR-ABL Dual Fusion probes (Abbott-Vysis, Downers Grove, USA) was performed in cases of culture failure. In case of additional cytogenetic abnormalities (ACyA), FISH with centromeric (AbbottVysis) and/or painting probes (Cambio Ltd., Cambridge, UK) was performed. Molecular response was assessed by nested RT-PCR (ref. 23 ) and from 2000 also by real-time quantitative reverse-transcriptase polymerase chain reactions (RQ-PCR). The detailed method for RQ-PCR was described previously 24 . CML phases were defined according to a study by Cortes et al. 25 . Sokal and Hasford scores were calculated in patients at diagnosis before introduction of any treatment, according to previously published formulas 26, 27 . Patients were evaluated for hematologic and cytogenetic (CyR) responses and their median duration met the ELN criteria with the exception of the first bone marrow punction done in 6 months instead of 3 months 28 . Complete hematologic response (CHR) was defined as platelet count less than 450x10 9 /L, white blood cell count (WBC) less than 10x10 9 /L, no immature granulo- /L. The initial dose of 1.5 or 3 MU was increased depending on the patient's tolerance to 9 or 10 MU daily within one month. In patients who did not achieve CHR with this dose and in cases with WBC>5x10 9 /L, hydroxyurea or subcutaneous Ara-C at a dose of 10 to 20 mg daily or oral Ara-C 40 mg daily was added in order to achieve WBC=4-2x10 9 /L with absolute neutrophil count over 1.0x10 9 /L. In cases with more prominent neutropenia or thrombocytopenia less than 50x10 9 /L, the dose of INF-α was reduced appropriately. The lowest dosage used in case of hematologic toxicity was 3 MU three times weekly. In patients who achieved negativity of BCR-ABL in nested RT-PCR with at least two-year duration dose of INF-α was reduced very slowly during one to two years. For the purpose of autologous hematopoietic stem cell transplantation (HSCT), peripheral stem cells were collected after priming with chemotherapy and G-CSF. The priming was timed early after diagnosis after successful cytoreduction. The graft was frozen using the ICE-CUBE programmed freezer after addition of albumin and 10% dimethyl sulphoxide. Oral high-dose busulfan was used for conditioning in all transplanted patients. Data on all transplantations were submitted to the EBMT database and some of the patients were included in the EBMT CML 99 study.
Data analysis and statistics
Since the whole group of 118 patients comprised some who were switched to other treatment options due to INF-α failure or adverse effects or were treated with INF-α for less than 12 months, a group of patients treated with INF-α for more than 12 months was analyzed separately. Patients switched to TKIs during the follow-up were censored at the time of TKI initiation in the overall survival (OS) estimation. Patients in whom allogeneic HSCT was performed were censored for analysis of OS at the time of HSCT. The OS was calculated from the first dose of INF-α and from the first CyR achieved. The prognostic impact of splenomegaly, initial hemoglobin levels, leukocyte and platelet counts, percentage of peripheral blasts, eosinophils and basophils, ACyA, age and influence of Sokal and Hasford (Euro) scores on the OS of the whole cohort and patients treated with INF-α for more than one year was evaluated.
The log-rank test, Mann-Whitney U test and Cox regression analysis were used in statistical evaluation 29 . The OS was calculated using the Kaplan-Meier method, with 5% level being considered as statistically significant 30 . Landmark analysis was performed to calculate the OS in patients who achieved CCyR that lasted over 12 months.
RESULTS
The study group comprised 118 consecutive adult Phpositive CML patients in the chronic phase of the disease at the time of diagnosis. Main characteristics of all 118 patients at the time of diagnosis are listed in Table 1 . In 11 patients, ACyA were detected and variant Ph chromosome was detected in 4 patients. INF-α in combination with hydroxyurea, thirty-two patients (27.0%) in combination with low-dose Ara-C and seven patients (5.9%) underwent autologous HSCT. After INF-α discontinuation, seventy-seven patients (65.3%) were switched to therapy with TKIs. Twelve patients (10.0%) underwent allogeneic HSCT. The treatment regimens are summarized in Table 2 .
General overview of achieved responses and reasons for INF-α discontinuation
As shown in Table 3 A total of 109 patients discontinued treatment with INF-α ( Table 4 ). The main reasons were a lack of hemato- Eleven patients had ACyA at the time of diagnosis (2 had trisomy 8, one inversion 17q, one deletion of chromosome Y, 3 had additional translocations and 4 other deletions). In these patients, INF-α was discontinued due to hematologic (3 patients) or cytogenetic resistance (1 patient), cytogenetic progression (2 patients) and evolution of the blastic phase (1 patient). In three patients, INF-α treatment was discontinued due to intolerance to the drug. In 6 patients, no CyR was achieved. Five patients were switched to imatinib. As of the date of this report,, 7 patients with ACyA at diagnosis have died, 3 patients are alive on imatinib and 1 patient with ACyA (trisomy 8) continues INF-α treatment after having achieved negativity of BCR-ABL in nested RT-PCR. Four additional patients had variant Ph chromosome at the time of diagnosis. One of them died in the blastic phase of CML while the others were switched to imatinib.
All factors mentioned in the Materials and Methods section were evaluated for their impact on prognosis (namely the overall survival) of the whole patient cohort. The percentage of peripheral blasts, leukocyte count (WBC>50x10 9 /L), splenomegaly, anemia (Hgb ≤110 g/L) and Sokal score had a statistical impact on the OS in univariate assessment but only the Sokal score remained significant in multivariate analysis. Each increase in Sokal risk score in different patients at the time of diagnosis (from low to intermediate and to high) was associated with a 2.03-fold (95% CI 1.31-3.16) increased risk of death (P=0.002).
INF-α was discontinued due to intolerance (17 patients; 27.9%), treatment failure (23 patients; 37.7%) or sustained negativity of BCR-ABL in nested RT-PCR (7 patients; 11.5%). A detailed overview of reasons for discontinuation with numbers of patients is shown in Table  4 . The most common adverse effects noted were flu-like syndrome, anorexia with significant weight loss, insomnia, allergic exanthema and liver toxicity. The most severe sideeffects were rare and involved nervous system disorders including Parkinson syndrome (1 patient), polyradiculitis (1 patient) and depression. One patient committed suicide as a consequence of depression probably caused by INF-α despite anti-depression treatment managed by a psychiatrist.
Survival and prognostic factors for patients treated with INF-α
Sixty-one patients treated with INF-α for a period of time longer than 12 months were eligible for estimation of the OS and evaluation of prognostic factors. Patients who started INF-α after 2000 and those who were treated for less than 12 months were excluded to prevent statistical bias from too short treatment that could modify response evaluation. The mean OS calculated from the first dose of INF-α and from the first CyR achieved was 137.0 months (95% CI 117.6-156.4) and 139.6 months (95% CI 120.5-158.8) with a probability of 5-year survival of 73% and 83%, respectively ( Fig. 2 and 3 (Fig. 4) . However, no significant difference in the OS was observed using Hasford score. Hemoglobin level at the time of diagnosis with 110 g/L as the cut-off was proved to be significant as a prognostic factor (P<0.0001) with the mean OS of 84. In a subgroup of 61 patients treated with INF-α for more than 12 months, CyR was analyzed and expressed as cumulative probability in Fig. 6 . Achieving first CyR irrespective of its quality was expected in a median of 9.0 months (95% CI 4.6-13.5). Clinically important responses (PCyR and CCyR) were expected to be achieved in a median of 20.0 months (95% CI 11.7-28.4). CCyR 6 . Cumulative probability of achievement of the first CyR in estimated time from the first INF-α dose. The upper curve shows cumulative probability of achievement of the first CyR regardless of its quality; the median time to CyR is 9 months (95% CI 4.6-13.5). The middle curve shows the cumulative probability of achievement of the first PCyR or CCyR whichever came first; the median time to the event is 20 months (95% CO 11.7-28.4). The lower curve shows the cumulative probability of achievement of the first CCyR; the median time to CCyR has been estimated at 40.8 months (95% CI 25.1-56.6).
achievement was estimated in a median of 40.8 months (95% CI 25.1-56.6) (Fig. 6 ).
Complete cytogenetic responders
Eighteen patients achieved their CCyR as a result of INF-α therapy in a median of 18.3 months (3.7-47.3) and maintained their response for a median of 64 months (Fig. 7) in complete responders who maintained their response for at least 12 months (16 patients) estimated mean OS of 175.9 months (95% CI 144.4-207.7) with a probability of approximate survival of 87% at 5 years. Nine complete responders achieved negativity of BCR-ABL in RT-PCR and six of them discontinued INF-α due to prolonged RT-PCR negativity. Of the patients who achieved only CCyR without achievement of RT-PCR negativity, 6 patients lost their CCyR during follow-up and were switched to treatment with TKIs. One patient continues on INF-α and is still in CCyR. One patient died without the loss of CCyR from suicide due to severe depression as mentioned above. INF-α therapy was a highly probable cause of depression in this case. One patient died in a sudden blastic transformation of CML 21 months after achievement of CCyR.
DISCUSSION
Despite various severe adverse effects related to INF-α therapy leading to INF-α discontinuation and numerous cases of treatment failure due to primary INF-α resistance or disease progression, there is a group of patients that may benefit from this treatment option. Our results correspond with those from the literature [13] [14] [15] 31 proving that complete cytogenetic and especially molecular responses achieved on INF-α were rather long-lasting. Moreover, achievement of negativity of BCR-ABL in RT-PCR by INF-α enabled cessation of the treatment in a larger proportion of patients as compared than those on imatinib. As mentioned in the Introduction, this may be explained by the immunomodulatory effects of INF-α and its capability to target CML stem cells.
In our study, the proportion of patients who achieved BCR-ABL negativity in RT-PCR was 7.6%, one of the highest of single-center intention-to-treat analyses published. Kantarjian et al. published the only single center analysis with 512 patients treated with INF-α-based regimens where 20 patients (3.9%) were defined as complete molecular responders in at least 2 negative RT-PCR tests without a subsequent positive result 14 . They concluded that achievement of CCyR and CMR was associated with excellent long-term event-free survival of the patients. In our study, a higher probability of CMR achievement was found and, unlike the Houston study, we did not observe isolated negativity results in nested RT-PCR testing. All our patients who achieved RT-PCR negativity never experienced recurrence of the disease. On the other hand, our analysis showed that despite a significant prognostic impact of CCyR on the OS, achievement of CCyR without BCR-ABL negativity in RT-PCR (CMR) does not automatically lead to "operational cure".
Although we excluded all patients treated with INF-α for a short period of time after the year 2000 from the final analysis, the 5-year OS achieved in our study group (70%) with subsequent TKI therapy was comparable to results in the literature. CML patients treated with INF-α, HSCT or TKIs in Germany from 1997-2001 achieved a 5-year OS of 71% (ref. 32 ). The median OS was not achieved 
Survival Function
Cumulative survival in our study group. However, more than a half of our patients treated with INF-α for more than 12 months finally failed to respond to the therapy and were switched to TKIs later on. Thus, these patients were censored in OS calculation at the time of TKI initiation. However, in our cohort of patients, achieving CCyR was confirmed to be associated with better prognosis and long-term survival with a 5-year OS of approximately 87%.
In univariate analysis, the percentage of peripheral blasts, leukocyte number (WBC>50x10 9 /L), splenomegaly, anemia (Hgb≤110 g/L) and Sokal score had a statistical impact on the OS for the whole group, and Sokal score, splenomegaly and hemoglobin level lower than 110 g/L for patients treated for more than one year. Only the Sokal score remained independently significant in multivariate analysis in both cohorts of patients. Neither age, nor white cell count or platelet count, or percentage of eosinophils and basophils had significantly impact on OS. In addition, we confirmed the poor prognosis of patients with ACyA at diagnosis treated with INF-α. On the other hand, we identified some features in blood count associated with achievement of molecular response and negativity of BCR-ABL in RT-PCR (ref. 33 ). However, this analysis should be viewed cautiously because of the low numbers of patients analyzed.
Although INF-α is no longer the front-line treatment option in CML management, it is still a possible alternative in patients with a good initial response to this treatment or those in whom therapy with TKIs is contraindicated. Because of its unique immunological effects and ability to target CML stem cells it has become an object of interest in novel clinical trials combining INF-α with TKIs (ref. [34] [35] [36] ). Combination regimens showed promising results in a German study using imatinib with INF-α as induction with subsequent INF-α alone as maintenance therapy inducing a progressive decline in BCR-ABL1 transcript levels and increase in CMR during the maintenance phase after imatinib discontinuation 37 . In this study, only 25% of patients experienced molecular relapse during a median of 5.3 months. In the French stop-imatinib STIM study, however, 61% of patients relapsed during the first 6 months after imatinib discontinuation 38 . According to the SPIRIT study, a phase III randomized trial organized by the French CML Group, combination regimen containing imatinib with PEG INF-α-2a rendered the highest rate of major molecular response (62%) compared with standard (41%) or high-dose imatinib (52%) (ref. 36 ). However, these results were not confirmed by the study carried out by authors from MD Anderson where no difference in major molecular response rates was observed in patients treated with high-dose imatinib only in comparison to those treated with the combination regimen containing high-dose imatinib, PEG INF-α-2b and granulocyte-macrophage colony-stimulating factor 34 .
There are very little data on immunological markers that could predict the therapeutic effect of INF-α. So far, it has been reported that the presence of PR1-specific cytotoxic lymphocytes is associated with responsiveness to INF-α (ref. 19 ). Our collaboration with Finnish authors revealed a unique plasma cytokine profile and increase in NK-cells and in T-lymphocyte subpopulation in patients able to discontinue INF-α (ref. 39 ). However, the predictive role of this specific profile needs to be confirmed in prospective studies in order to assess its actual impact on INF-α treatment response and to help select patients with a higher probability of achieving CMR with INF-α therapy.
CONCLUSIONS
To summarize, our single-center retrospective study which analyzed the results of INF-α therapy corresponds with the reported literature and contributes to the ongoing quest for different ways towards permanent cure of CML. We found 15.3% and 7.6% achievement rates of CCyR and BCR-ABL negativity in RT-PCR, respectively, after INF-α in a group of 118 consecutive patients with chronic phase CML treated in a defined region in an intentionto-treat retrospective analysis. Unlike patients with only CCyR, the majority of whom lost CCyR despite continuing INF-α therapy and later required imatinib, patients who achieved BCR-ABL negativity in nested RT-PCR had excellent long-term outcome.
